Terapötik İlaç İzlemi
Özet
Terapötik ilaç izlemi (Tİİ), dar terapötik aralığa sahip ilaçların çeşitli biyolojik sıvılardaki konsantrasyonlarının ölçülüp yorumlanmasıyla, tedavide optimum etkinliği sağlarken toksisiteyi en aza indirmeyi amaçlayan kritik bir sağlık hizmetidir. Özellikle fizyolojileri ve ilaç kinetikleri sürekli değişkenlik gösteren yoğun bakım hastalarında, dozların bireyselleştirilmesini ve etkinliğin artırılmasını sağlar. Tİİ'nin başarılı olabilmesi için ilaçların kararlı duruma (Css) ulaşma süreleri, uygulama yolları, hastanın böbrek/karaciğer fonksiyonları ve doğru örnek alma zamanlaması (vadi veya pik düzeyleri) gibi biyolojik faktörlerin titizlikle göz önünde bulundurulması gerekir. Yoğun bakım ünitelerinde yaygın olarak kullanılan vankomisin, aminoglikozitler, digoksin, fenitoin, valproat ve teofilin gibi ilaçların her birinin kendine özgü hedef terapötik aralıkları ve örnekleme protokolleri bulunmaktadır. Yapılan çalışmalar, doğru zamanlama ve klinik parametrelerle uygulanan Tİİ rehberliğindeki tedavilerin, hastaların maruz kaldığı advers etkileri belirgin şekilde azalttığını, klinik sonuçları iyileştirdiğini ve hastaneler için maliyet etkililiği sağladığını açıkça ortaya koymaktadır.
Therapeutic drug monitoring (TDM) is a critical healthcare service that aims to ensure optimum efficacy while minimizing toxicity in treatment by measuring and interpreting the concentrations of narrow therapeutic index drugs in various biological fluids. It enables the individualization of doses and enhances efficacy, particularly in intensive care patients whose physiology and drug kinetics constantly fluctuate. For TDM to be successful, biological factors such as the time required for drugs to reach steady-state (Css), administration routes, patient's renal/hepatic functions, and precise sampling timing (trough or peak levels) must be meticulously considered. Commonly used drugs in intensive care units, including vancomycin, aminoglycosides, digoxin, phenytoin, valproate, and theophylline, each possess distinct target therapeutic ranges and sampling protocols. Studies clearly demonstrate that TDM-guided therapies, when implemented with correct timing and clinical parameters, significantly reduce adverse events, improve clinical outcomes, and provide cost-effectiveness for hospitals.
Referanslar
Demirkan K. Yoğun bakım ünitesinde dar terapötik aralıklı ilaç kullanımı. J Crit Intensive Care. 2005, 5(4):240-246.
Demirkan K. Terapötik ilaç monitorizasyonu. J Crit Intensive Care. 2007;7(3):365-369.
Kang JS, Lee MH. Overview of therapeutic drug monitoring. The Korean Journal of Internal Medicine. 2009;24:1-10.
Whittlesea C, Hodson K. Clinical pharmacy and therapeutics (6th ed.). Elsevier; 2019.
Reid LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit. 1990;12:72–78.
Mohd H. Abdul‐Aziz, Jan‐Willem C. Alffenaar, Matteo Bassettiet al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Medicine, 2020;46(6):1127-1153.
McFadyen ML, Miller R, Juta M et al. The relevance of a irst world therapeutic drug monitoring service to the treatment of epilepsy in third world conditions. South Afr Med J. 1990;78:587–590.
Touw DJ, Neef C, Thomson AH et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005; 1:7–10.
Kayaalp, S. Oğuz. Rasyonel tedavi yönünden tıbbi farmakoloji. Hacettepe Taş Kitapçılık Limited Şti., 2005.
The Sanford Guide to Antimicrobial Therapy. (Antimicrobial Therapy, Inc., Sperryville, ABD)
Shah S, Greg B, Andreas F. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015;16(2):147-153.
Onufrak NJ, Alan F, Daniel G. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin Ther. 2016;38(9):1930-1947.
Álvarez O, Jose CP, Manuel R et al. Pharmacokinetic assessment of vancomycin loading dose in critically ill patients. Antimicrob Agents Chemother. 2017;61(8):e00280-17.
Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2020;71(6):1361-1364.
Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000; 5(1):3-22.
Charfi R, Sassi MB, Gaieset EM et al. Digoxin therapeutic drug monitoring: age influence and adverse events Suivi thérapeutique pharmacologique de la digoxine: influence de l’âge et effets indésirables. La Tunisie Medicale. 2020;98(01):35-40.
Lopes RD, Rordorf R, De Ferrari GM et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063-1074.
Pagana KD, Pagana TJ, Pagana TN. Mosby’s diagnostic & laboratory test reference. 14th ed. St. Louis, Mo: Elsevier; 2019.
Ibrahim NAM. An up-to-date review of digoxin toxicity and its management. Int J Res Pharm Pharm Sci. 2019;4(3):59-64.
Southwood R, Fleming VH, Huckaby G. Concepsts in clinical pharmacoknetics (7th ed.). Bethesda, ASHP; 2018.
Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28(11):1391-1400.
Wu MF, WH. Phenytoin: A guide to therapeutic drug monitoring. Proc Singapore Healthc. 2013;22(3);198-202.
Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit. 2018;40:526–548.
UpToDate® [Internet]. (Wolters Kluwer Health, Massachusetts, ABD)
Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J Clin Pharmacol. 2011; 67:521–526.
Rugelj N, Trobec KČ, Pišlar M etal. Evaluation of theophylline therapeutic drug monitoring service. Zdrav Vestn. 2015; 84:191–202.
